• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JCI Insight . IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN

tetano

Editor, Senior Moderator
JCI Insight


. 2024 May 21;9(13):e171830.
doi: 10.1172/jci.insight.171830. IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN

Abigail D Solstad[SUP] 1 2 [/SUP], Parker J Denz[SUP] 1 2 [/SUP], Adam D Kenney[SUP] 1 2 [/SUP], Najmus S Mahfooz[SUP] 1 2 [/SUP], Samuel Speaks[SUP] 1 [/SUP], Qiaoke Gong[SUP] 1 [/SUP], Richard T Robinson[SUP] 1 2 [/SUP], Matthew E Long[SUP] 3 4 [/SUP], Adriana Forero[SUP] 1 2 3 [/SUP], Jacob S Yount[SUP] 1 2 [/SUP], Emily A Hemann[SUP] 1 2 3 [/SUP]



Affiliations
Abstract

Optimization of protective immune responses against SARS-CoV-2 remains an urgent worldwide priority. In this regard, type III IFN (IFN-λ) restricts SARS-CoV-2 infection in vitro, and treatment with IFN-λ limits infection, inflammation, and pathogenesis in murine models. Furthermore, IFN-λ has been developed for clinical use to limit COVID-19 severity. However, whether endogenous IFN-λ signaling has an effect on SARS-CoV-2 antiviral immunity and long-term immune protection in vivo is unknown. In this study, we identified a requirement for IFN-λ signaling in promoting viral clearance and protective immune programming in SARS-CoV-2 infection of mice. Expression of both IFN and IFN-stimulated gene (ISG) in the lungs were minimally affected by the absence of IFN-λ signaling and correlated with transient increases in viral titers. We found that IFN-λ supported the generation of protective CD8 T cell responses against SARS-CoV-2 by facilitating accumulation of CD103+ DC in lung draining lymph nodes (dLN). IFN-λ signaling specifically in DCs promoted the upregulation of costimulatory molecules and the proliferation of CD8 T cells. Intriguingly, antigen-specific CD8 T cell immunity to SARS-CoV-2 was independent of type I IFN signaling, revealing a nonredundant function of IFN-λ. Overall, these studies demonstrate a critical role for IFN-λ in protective innate and adaptive immunity upon infection with SARS-CoV-2 and suggest that IFN-λ serves as an immune adjuvant to support CD8 T cell immunity.

Keywords: Immunology; Infectious disease; Innate immunity; Mouse models; T cells.

 
Back
Top Bottom